GlassScriptPhysician profile
Catherine L Buswell
NPI 1184657165
$4,814.40
in general payments reported to CMS, 2019-2025
18 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $770 · 2023: $974 · 2024: $1,068 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,588 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,587.86 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $832.93 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $751.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $728.68 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $545.50 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $303.59 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $300.64 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $298.25 | 2021-2025 | Invega, Spravato |
| Lundbeck LLC | $231.25 | 2021-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $154.83 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $130.69 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $128.75 | 2023-2025 | Ingrezza |
| Noven Therapeutics, LLC | $125.34 | 2021-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $99.55 | 2021-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $46.92 | 2022-2023 | Trintellix |
| Tris Pharma INC | $43.41 | 2023-2024 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $36.93 | 2021 | |
| Almatica Pharma LLC | $36.70 | 2021-2023 | Citalopram, Gralise, Venlafaxine |
| Idorsia Pharmaceuticals US INC | $18.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Buswell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.